The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges
出版年份 2015 全文链接
标题
The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges
作者
关键词
-
出版物
BRITISH JOURNAL OF PHARMACOLOGY
Volume 172, Issue 23, Pages 5512-5522
出版商
Wiley
发表日期
2014-12-02
DOI
10.1111/bph.13029
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Metformin Protects Endothelial Function in Diet-Induced Obese Mice by Inhibition of Endoplasmic Reticulum Stress Through 5′ Adenosine Monophosphate–Activated Protein Kinase–Peroxisome Proliferator–Activated Receptor δ Pathway
- (2014) Wai San Cheang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- In SilicoIdentification of Potent PPAR-γAgonists from Traditional Chinese Medicine: A Bioactivity Prediction, Virtual Screening, and Molecular Dynamics Study
- (2014) Kuan-Chung Chen et al. Evidence-based Complementary and Alternative Medicine
- Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
- (2013) A. Michael Lincoff et al. AMERICAN HEART JOURNAL
- Results of a reevaluation of cardiovascular outcomes in the RECORD trial
- (2013) Kenneth W. Mahaffey et al. AMERICAN HEART JOURNAL
- Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator–Activated Receptor α–Dependent and Independent Mechanisms in Human Endothelial Cells
- (2013) Corine Glineur et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Peroxisome Proliferator–Activated Receptor δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice
- (2013) Lazar A. Bojic et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Honokiol: A non-adipogenic PPARγ agonist from nature
- (2013) Atanas G. Atanasov et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors
- (2013) Stephen P.H. Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
- (2013) Stephen P.H. Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors
- (2013) Stephen P.H. Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension
- (2013) María José Zarzuelo et al. CARDIOVASCULAR RESEARCH
- PPAR-γ agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow
- (2013) Hui-Feng Zhang et al. CELL BIOLOGY INTERNATIONAL
- Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights
- (2013) Carlos Vallarino et al. CLINICAL DRUG INVESTIGATION
- The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
- (2013) Adam J. Pawson et al. NUCLEIC ACIDS RESEARCH
- The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis
- (2013) Wendy Marder et al. Journal of the American Heart Association
- Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease
- (2012) Chiara Marchesi et al. CARDIOVASCULAR RESEARCH
- Coronary Flow Velocity Reserve is Improved by PPAR-α Agonist Fenofibrate in Patients with Hypertriglyceridemia
- (2012) Guang Wang et al. Cardiovascular Therapeutics
- Cullin-3 Regulates Vascular Smooth Muscle Function and Arterial Blood Pressure via PPARγ and RhoA/Rho-Kinase
- (2012) Christopher J. Pelham et al. Cell Metabolism
- Loss of Perivascular Adipose Tissue on Peroxisome Proliferator–Activated Receptor-γ Deletion in Smooth Muscle Cells Impairs Intravascular Thermoregulation and Enhances Atherosclerosis
- (2012) Lin Chang et al. CIRCULATION
- PPAR Activation Protects Endothelial Function in Diabetic Mice
- (2012) X. Y. Tian et al. DIABETES
- Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
- (2012) Ying Chen et al. DIABETES
- Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats
- (2012) Ana María Quintela et al. FREE RADICAL BIOLOGY AND MEDICINE
- Peroxisome Proliferator-Activated Receptor-γ Ameliorates Pulmonary Arterial Hypertension by Inhibiting 5-Hydroxytryptamine 2B Receptor
- (2012) Yahan Liu et al. HYPERTENSION
- Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine
- (2012) Kuan-Chung Chen et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells
- (2012) Estelle Woldt et al. Nature Communications
- Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
- (2011) Yun-Jung Choi et al. ATHEROSCLEROSIS
- Adiponectin Is Required for PPARγ-Mediated Improvement of Endothelial Function in Diabetic Mice
- (2011) Wing Tak Wong et al. Cell Metabolism
- The PPAR-RXR Transcriptional Complex in the Vasculature
- (2011) Jorge Plutzky CIRCULATION RESEARCH
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- Antihypertensive Effects of Peroxisome Proliferator-Activated Receptor-β Activation in Spontaneously Hypertensive Rats
- (2011) María José Zarzuelo et al. HYPERTENSION
- Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
- (2011) Jang Hyun Choi et al. NATURE
- Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase
- (2010) Chi Yung Yuen et al. CARDIOVASCULAR RESEARCH
- Rosiglitazone Attenuates Endothelin-1–Induced Vasoconstriction by Upregulating Endothelial Expression of Endothelin B Receptor
- (2010) Jianwei Tian et al. HYPERTENSION
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
- (2010) David J. Graham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation
- (2010) Claire B. Pollock et al. PPAR Research
- Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation
- (2009) Federico Biscetti et al. Cardiovascular Diabetology
- Vascular Smooth Muscle Cell–Selective Peroxisome Proliferator–Activated Receptor-γ Deletion Leads to Hypotension
- (2009) Lin Chang et al. CIRCULATION
- Endothelium-Dependent Vasodilator Effects of Peroxisome Proliferator-Activated Receptor Agonists via the Phosphatidyl-Inositol-3 Kinase-Akt Pathway
- (2009) R. Jimenez et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- PPARγ1-Induced Caveolin-1 Enhances Cholesterol Efflux and Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
- (2009) Qin Hu et al. JOURNAL OF VASCULAR RESEARCH
- Separation, Characterization and Dose-Effect Relationship of the PPARγ-Activating Bio-Active Constituents in the Chinese Herb Formulation ‘San-Ao Decoction’
- (2009) Ling Zhou et al. MOLECULES
- Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
- (2008) Robert Wilcox et al. AMERICAN HEART JOURNAL
- Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: Therapeutic implications for cardiovascular diseases
- (2008) Dimitris Tousoulis et al. ATHEROSCLEROSIS
- Fibrate Therapy
- (2008) Joshua Remick et al. Cardiology in Review
- Interference with PPARγ Function in Smooth Muscle Causes Vascular Dysfunction and Hypertension
- (2008) Carmen M. Halabi et al. Cell Metabolism
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2008) R. Scott et al. DIABETES CARE
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PPAR regulates multiple proinflammatory pathways to suppress atherosclerosis
- (2008) G. D. Barish et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice
- (2007) Po-Hsun Huang et al. BIOMEDICINE & PHARMACOTHERAPY
- Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or oedema?
- (2007) S Mittra et al. BRITISH JOURNAL OF PHARMACOLOGY
- Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial
- (2007) Bela F. Asztalos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
- (2007) Frank J. Gonzalez et al. TOXICOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started